CYCLERION THERAPEUTICS, INC. Operating Lease, Impairment Loss
CYCLERION THERAPEUTICS, INC. (CYCN) reported Operating Lease, Impairment Loss of $3.30 million for the 12-month period ending 2023-12-31, per its 10-K/A filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2025-11-12
- CYCLERION THERAPEUTICS, INC. operating lease, impairment loss for the quarter ending 2023-12-31 was $0.00.
- CYCLERION THERAPEUTICS, INC. operating lease, impairment loss for the quarter ending 2023-09-30 was $3.30M.
- CYCLERION THERAPEUTICS, INC. operating lease, impairment loss for fiscal 2023 was $3.30M.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | $3.30M derived: sum of 2 quarters · filed 2025-11-12 | $3.30M 10-K/A · filed 2025-11-12 | |
| 2023-09-30 | $3.30M 10-Q · filed 2023-11-13 | $3.30M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |